The Acute Leukemia Advocates Network (ALAN) works with a range of pharmaceutical companies, to ensure that the interests of acute leukemia patients are taken into account during the development of new treatments.
Whilst we receive funding from the pharmaceutical industry, we are wholly independent of these commercial organisations, including our decision making.
Rationale for working with the pharmaceutical industry
ALAN recognises the importance of collaborative working with all stakeholders working in the field of acute leukemia. Collaborative working and financial support are essential to ensure that we can continue to carry out our work. It enables us to obtain information, achieve common goals and provide support that would not otherwise be possible. But we recognise the need for such partnerships to be transparent in order to ensure we retain our independence. As such, we are committed to being transparent about the funding we receive from the pharmaceutical industry.
We are committed to maintaining our independence and to avoid any support that could adversely affect our reputation. We will proactively seek a variety of funding sources and will not accept any support that threatens to compromise our independence. ALAN will not promote companies, products or services. This is made clear to all companies at the first point of contact. If a company makes any attempt to coerce ALAN to promote a product, or does not conform with the memorandum of understanding, we will reject the funds or terminate any ongoing project.
ALAN receives funding from a range of pharmaceutical companies and we are committed to being transparent about the funding we receive. As such, we would like to thank the following companies for their support in 2020 and 2021: Abbvie, Adaptive, Agios, Amgen, Astellas, Autolus, Bristol-Myers Squibb, Daiichi Sankyo, Gilead/Kite, Glycostem, Incyte, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Roche, Servier and Takeda.
We would like to thank our 2022 supporters for their continuous support: